Navigation Links
Life Sciences Industry Reaches Crossroad Say Noted Pillsbury Attorneys
Date:3/17/2008

Appeals for the Federal Circuit and examiners from the U.S. Patent and Trademark Office.

About Pillsbury

Pillsbury Winthrop Shaw Pittman LLP is a dynamic full-service law firm with market-leading strengths in the life science, energy, financial services, real estate and technology sectors. Our lawyers serve clients throughout the U.S. and internationally from key global financial centers including New York, London, Tokyo and Shanghai. Industry-driven client teams and a multidisciplinary approach to crucial business issues of the day ensure that clients receive insightful counsel which spans the full breadth of a matter.

The 2008 Corporate Counsel survey of in-house counsel at Fortune 500 companies named Pillsbury a "Go-To Firm" in six practice areas -- corporate transactions, international, Intellectual Property, litigation, labor and employment and securities.


'/>"/>
SOURCE Pillsbury Winthrop Shaw Pittman LLP
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
5. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
6. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
7. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
8. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
9. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
10. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
11. The Pittsburgh Life Sciences Greenhouse Adds New Companies to its Investment Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... -- In an article published and posted online today, ... review the clinical aspects of diseases caused by 5 ... article, "Clinical Management of Potential Bioterrorism-Related Conditions," was published ... New England Journal of Medicine . ... Tom Inglesby—review the clinical management of conditions resulting from ...
(Date:3/4/2015)... BROOKLYN, N.Y. , March 4, 2015  Brooklyn ... treat their acute and chronic pain and injuries. ... to announce the grand opening of his NJS Physical ... NY on Thursday, March 5, 2015. Health ... the facility, which is located at 1178 Flatbush Avenue. ...
(Date:3/4/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/nqxxt3/biomarkers ) ... report "Biomarkers - Technologies, Markets and Companies" ... report follows the broad definition of a biomarker ... and evaluated as an indicator of normal biological ... to a therapeutic intervention. Tests based on biomarkers ...
(Date:3/4/2015)... 2015 /CNW/ - Resverlogix Corp. (TSX:RVX) (the "Company") ... collaborative research program with Emerald Logic, a ... Evolution Technology (FACET), Emerald Logic analyzed Resverlogix,s ... from each of 798 patients who participated ... ASSERT, SUSTAIN and ASSURE. The objective of ...
Breaking Biology Technology:Latest Clinical Information On Bioterrorism Threats 2NJS Physical Medicine & Rehabilitation Opening on Flatbush Avenue, Brooklyn, NY 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4
... WALTHAM, Mass., Nov. 10, 2011 Interleukin Genetics, Inc. ... the third quarter ended September 30, 2011. Total ... $765,000, compared to $545,000 for the same period in the ... revenue. Research and development expenses were $325,000 ...
... Inc., a global, full-service testing laboratory with more than ... organs, cells, tissues and implantable biologic products and devices, ... private companies, as judged by the annual ColoradoBiz ... Top 250 Private Companies list is an annual ranking ...
... England Biolabs (NEB), in its continuing commitment to open ... database covering DNA polymerase biochemistry, genetics and structural biology. ... and maintained by NEB), Polbase summarizes the information that ... it easy for researchers to interrogate and use. Polbase ...
Cached Biology Technology:Interleukin Genetics Reports Third Quarter 2011 Financial Results 2Interleukin Genetics Reports Third Quarter 2011 Financial Results 3Interleukin Genetics Reports Third Quarter 2011 Financial Results 4LABS, Inc. Among Colorado's Top Private Companies 2New England Biolabs Introduces Polbase, an Information Repository of Scientific Data for Polymerase Researchers 2
(Date:2/5/2015)... , Jan. 30, 2015  It is gratifying to ... and potential for genomic science as a means to ... prevention and treatment.  I was honored to participate in ... precision medicine program. Since the 1980s ... of genomics—from the first sequenced genome of a free ...
(Date:1/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced ... Overview" report to their offering. , ... an individual is who she/he is claiming to be, and ... person,s unique physical characteristics, such as fingerprint, hand or palm ...
(Date:1/22/2015)... 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading source of biometrics ... its new website design. "When we launched FindBiometrics ... Peter O,Neill , founder and CEO of FindBiometrics. "Now ... involvement from the key players on a very broad scale.  ...
Breaking Biology News(10 mins):J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2
... San Diego, Calif. Glioblastoma, the most common and lethal ... because the tumors rapidly become resistant to therapy. As cancer ... growth and drug resistance, they are discovering molecular pathways that ... deadly cancer. Scientists at the Ludwig Institute for Cancer ...
... at the Society of Toxicology,s Annual Meeting and ToxExpo ... that have received growing public attention over the past ... explore how the development of an epidemiological database that ... risk assessment of arsenic in food. While epidemiological studies ...
... Vision and Ophthalmology 2013 Annual Meeting will feature lectures ... the organization,s five-day conference, May 5 9 in ... Series will include Oliver Smithies, DPhil; Roger Tsien, PhD ... University of North Carolina at Chapel Hill, is a ...
Cached Biology News:Novel combination therapy shuts down escape route, killing glioblastoma tumor cells 2Scientists explore topical health issues at meeting in Texas 23 distinguished keynote speakers to present during ARVO 2013 Annual Meeting 2
... , Ultima II Series ... Ultima II represents the finest, most enhanced ... and blood bank configurations, each Ultima II ... system with built-in voltage boost and surge ...
...
Verotoxin IIbeta (457)...
Features , Designed to assist users in applying domed caps to tube strips and plates , Minimises the pressure required to seal the caps effectively , Enables multiple tubes to be sealed simultaneousl...
Biology Products: